Format

Send to

Choose Destination
Oncotarget. 2017 Feb 14;8(7):12108-12119. doi: 10.18632/oncotarget.14520.

Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus.

Yu TZ1,2, Zhang W1,2, Liu QX1,2, Li WH3, Ma JQ1,2, Zhang ZH1,2, Yang MJ1,2, Wang JH1,2, Chen B4, Zeng SC4, Luo JJ1,2, Liu LX1,2, Yan ZP1,2.

Author information

1
Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
2
Shanghai Institute of Medical Imaging, Shanghai, China.
3
Department of Interventional Radiology, Yancheng Third People's Hospital, Southeast University, Yancheng, China.
4
Department of Radiotherapy, Zhongshan Hospital, Fudan University, Shanghai, China.

Abstract

Hepatocellular carcinoma (HCC) patients with main portal vein tumor thrombus have a median survival time of only about 4 months. We therefore compared the safety and efficacy of endovascular brachytherapy (EVBT) and sequential three-dimensional conformal radiotherapy (3-DCRT). From a cohort of 176 patients, we treated 123 with EVBT using iodine-125 seed strands (group A) and the remaining 53 with sequential 3-DCRT (group B). Overall survival, progression free survival and stent patency characteristics were compared between the two groups. Our analysis demonstrated a median survival of 11.7 ± 1.2 months in group A versus 9.5 ± 1.8 months in group B (p = 0.002). The median progression free survival was 5.3 ± 0.7 months in groupA versus 4.4 ± 0.4 months in group B (p = 0.010). The median stent patency period was 10.3 ± 1.1 months in group A versus 8.7 ± 0.7 months in group B (p = 0.003). Therefore, as compared to sequential 3-DCRT, EVBT combined with portal vein stenting and TACE improved overall survival of HCC patients with main portal vein tumor thrombus.

KEYWORDS:

endovascular brachytherapy; hepatocellular carcinoma; main portal vein; three-dimensional conformal radiotherapy; tumor thrombus

PMID:
28076848
PMCID:
PMC5355329
DOI:
10.18632/oncotarget.14520
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center